MA39145A1 - Dérivés de pipérazine ayant une activité multimode contre la douleur - Google Patents
Dérivés de pipérazine ayant une activité multimode contre la douleurInfo
- Publication number
- MA39145A1 MA39145A1 MA39145A MA39145A MA39145A1 MA 39145 A1 MA39145 A1 MA 39145A1 MA 39145 A MA39145 A MA 39145A MA 39145 A MA39145 A MA 39145A MA 39145 A1 MA39145 A1 MA 39145A1
- Authority
- MA
- Morocco
- Prior art keywords
- multimode
- activity against
- piperazine derivatives
- against pain
- compounds
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title abstract 2
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 2
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 102000051367 mu Opioid Receptors Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108010085082 sigma receptors Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 108020001612 μ-opioid receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La présente invention concerne des composés présentant une activité pharmacologique double envers à la fois le récepteur sigma (s), et le récepteur µ-opioïde, et plus particulièrement des composés de pipérazine qui ont cette activité pharmacologique, des procédés de préparation de tels composés, des compositions pharmaceutiques les comprenant, et leur utilisation en thérapie, en particulier pour le traitement de la douleur.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13384006 | 2013-12-20 | ||
PCT/EP2014/078852 WO2015092009A1 (fr) | 2013-12-20 | 2014-12-19 | Dérivés de pipérazine ayant une activité multimode contre la douleur |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39145A1 true MA39145A1 (fr) | 2017-10-31 |
MA39145B1 MA39145B1 (fr) | 2018-05-31 |
Family
ID=49998042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39145A MA39145B1 (fr) | 2013-12-20 | 2014-12-19 | Dérivés de pipérazine ayant une activité multimode contre la douleur |
Country Status (17)
Country | Link |
---|---|
US (2) | US10351535B2 (fr) |
EP (1) | EP3083563A1 (fr) |
JP (1) | JP6553615B2 (fr) |
KR (1) | KR20160098506A (fr) |
CN (1) | CN105829287B (fr) |
AU (1) | AU2014368368C1 (fr) |
CA (1) | CA2932051A1 (fr) |
IL (1) | IL245808B (fr) |
MA (1) | MA39145B1 (fr) |
MX (1) | MX2016008130A (fr) |
MY (1) | MY179509A (fr) |
PH (1) | PH12016500978A1 (fr) |
RU (1) | RU2709482C1 (fr) |
SG (1) | SG10201805267UA (fr) |
TN (1) | TN2016000203A1 (fr) |
UA (1) | UA120754C2 (fr) |
WO (1) | WO2015092009A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107922397A (zh) * | 2015-07-29 | 2018-04-17 | 埃斯蒂文博士实验室股份有限公司 | 针对疼痛具有多模式活性的取代的酰胺衍生物 |
CN107922384A (zh) * | 2015-07-29 | 2018-04-17 | 埃斯蒂文博士实验室股份有限公司 | 对疼痛具有多模式活性的酰胺衍生物 |
ES2823588T3 (es) * | 2016-05-20 | 2021-05-07 | Esteve Pharmaceuticals Sa | Derivados de tetrahidropirano que tienen actividad multimodal contra el dolor |
EP3600289A4 (fr) * | 2017-03-21 | 2020-08-05 | Temple University - Of The Commonwealth System of Higher Education | Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques |
WO2018175188A1 (fr) * | 2017-03-21 | 2018-09-27 | Temple University-Of The Commonwealth System Of Higher Education | Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation |
MA54133B1 (fr) | 2018-03-08 | 2022-01-31 | Incyte Corp | Composés d'aminopyrazine diol utilisés comme inhibiteurs de pi3k-y |
WO2020010003A1 (fr) | 2018-07-02 | 2020-01-09 | Incyte Corporation | DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ |
EP3753932A1 (fr) * | 2019-06-17 | 2020-12-23 | Esteve Pharmaceuticals, S.A. | Dérivés bicycliques substitués ayant une activité pluri-modale contre la douleur |
WO2022187206A1 (fr) * | 2021-03-01 | 2022-09-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Ligands à double cible des récepteurs des opiacés mu et dopaminergiques d3 ; préparation et utilisation correspondants |
WO2024105225A1 (fr) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2580648B1 (fr) | 1985-04-17 | 1987-05-15 | Adir | Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant |
DK93087A (da) * | 1986-02-27 | 1987-08-28 | Duphar Int Res | Hidtil ukendte aryl substituerede (n-piperidinyl)methyl- og (n-piperazinyl)methylazoler med antipsykotiske egenskaber |
SE0103818D0 (sv) * | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
US7678791B2 (en) * | 2006-07-12 | 2010-03-16 | Cumbre Ip Ventures, L.P. | Nitroheteroaryl-containing rifamycin derivatives |
CA2656715A1 (fr) * | 2006-07-21 | 2008-01-24 | Irm Llc | Composes et compositions utilises en tant qu'inhibiteurs de l'itpkb |
AU2007314342B2 (en) * | 2006-10-31 | 2013-02-21 | Merck Sharp & Dohme Corp. | Anilinopiperazine Derivatives and methods of use thereof |
AU2007338408B2 (en) | 2006-12-27 | 2012-07-26 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
EP1982714A1 (fr) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-aminés |
CN101679370A (zh) | 2007-04-16 | 2010-03-24 | 格吕伦塔尔有限公司 | 香草素受体配体及其在制备药物中的用途 |
PT2155717E (pt) | 2007-05-11 | 2012-12-21 | Lilly Co Eli | 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil-pirazinas e -piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2- fenil-piridinas como antagonistas do recetor 5-ht7 |
WO2008157844A1 (fr) | 2007-06-21 | 2008-12-24 | Forest Laboratories Holdings Limited | Nouveaux dérivés de pipérazine en tant qu'inhibiteurs de stéaroyl-coa désaturase |
TW200914020A (en) | 2007-08-28 | 2009-04-01 | Lilly Co Eli | Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists |
BRPI0815327A2 (pt) | 2007-08-31 | 2015-12-15 | Purdue Pharma Lp | "compostos de piperidina do tipo quinoxalina substituída e os usos destes" |
WO2010046780A2 (fr) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Composés antiviraux |
WO2010054006A1 (fr) * | 2008-11-04 | 2010-05-14 | Chemocentryx, Inc. | Modulateurs du cxcr7 |
US8853202B2 (en) * | 2008-11-04 | 2014-10-07 | Chemocentryx, Inc. | Modulators of CXCR7 |
EP2375899B1 (fr) | 2009-01-12 | 2015-02-25 | Array Biopharma Inc. | Composés contenant de la pipéridine et leur utilisation dans le traitement du diabète |
NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
EP2395003A1 (fr) * | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Composés pyrazoliques en tant qu'inhibiteurs du récepteur sigma |
CN102918031A (zh) * | 2010-05-28 | 2013-02-06 | 通用电气健康护理有限公司 | 放射标记的化合物及其方法 |
-
2014
- 2014-12-19 MX MX2016008130A patent/MX2016008130A/es unknown
- 2014-12-19 US US15/106,423 patent/US10351535B2/en not_active Expired - Fee Related
- 2014-12-19 UA UAA201607879A patent/UA120754C2/uk unknown
- 2014-12-19 EP EP14815384.4A patent/EP3083563A1/fr not_active Withdrawn
- 2014-12-19 MA MA39145A patent/MA39145B1/fr unknown
- 2014-12-19 CA CA2932051A patent/CA2932051A1/fr not_active Abandoned
- 2014-12-19 KR KR1020167019809A patent/KR20160098506A/ko not_active Application Discontinuation
- 2014-12-19 TN TN2016000203A patent/TN2016000203A1/en unknown
- 2014-12-19 MY MYPI2016701867A patent/MY179509A/en unknown
- 2014-12-19 AU AU2014368368A patent/AU2014368368C1/en not_active Ceased
- 2014-12-19 CN CN201480069503.2A patent/CN105829287B/zh not_active Expired - Fee Related
- 2014-12-19 SG SG10201805267UA patent/SG10201805267UA/en unknown
- 2014-12-19 JP JP2016539896A patent/JP6553615B2/ja not_active Expired - Fee Related
- 2014-12-19 RU RU2016129110A patent/RU2709482C1/ru not_active IP Right Cessation
- 2014-12-19 WO PCT/EP2014/078852 patent/WO2015092009A1/fr active Application Filing
-
2016
- 2016-05-24 IL IL245808A patent/IL245808B/en active IP Right Grant
- 2016-05-25 PH PH12016500978A patent/PH12016500978A1/en unknown
-
2019
- 2019-05-30 US US16/426,024 patent/US10745361B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TN2016000203A1 (en) | 2017-10-06 |
US10745361B2 (en) | 2020-08-18 |
WO2015092009A1 (fr) | 2015-06-25 |
JP6553615B2 (ja) | 2019-07-31 |
AU2014368368C1 (en) | 2019-06-27 |
PH12016500978A1 (en) | 2016-06-20 |
MA39145B1 (fr) | 2018-05-31 |
SG10201805267UA (en) | 2018-07-30 |
AU2014368368B2 (en) | 2019-01-31 |
IL245808B (en) | 2020-03-31 |
EP3083563A1 (fr) | 2016-10-26 |
UA120754C2 (uk) | 2020-02-10 |
IL245808A0 (en) | 2016-08-02 |
CN105829287A (zh) | 2016-08-03 |
CN105829287B (zh) | 2019-08-27 |
RU2016129110A (ru) | 2018-01-23 |
US10351535B2 (en) | 2019-07-16 |
MY179509A (en) | 2020-11-09 |
KR20160098506A (ko) | 2016-08-18 |
JP2016540792A (ja) | 2016-12-28 |
RU2709482C1 (ru) | 2019-12-18 |
CA2932051A1 (fr) | 2015-06-25 |
AU2014368368A1 (en) | 2016-07-07 |
MX2016008130A (es) | 2016-10-13 |
US20190276415A1 (en) | 2019-09-12 |
US20170001967A1 (en) | 2017-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39145A1 (fr) | Dérivés de pipérazine ayant une activité multimode contre la douleur | |
EA201792047A1 (ru) | Новые соединения | |
MA41179A (fr) | Composés inhibiteurs de parg | |
MA35869B1 (fr) | Composés imidazopyrrolidinone | |
MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
MA39725B1 (fr) | Compositions pharmaceutiques de composés thérapeutiquement actifs | |
EA201290209A1 (ru) | Новые модуляторы бензопиран киназы | |
MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
MA38039A1 (fr) | Composés de céphem substitués en position 2 | |
MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
MA44948A1 (fr) | Inhibiteurs de bace 1 | |
MA37946A1 (fr) | Traitement de la polyarthrite rhumatoïde | |
MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
MA35816B1 (fr) | Dérivés d'aniline, leur préparation et leur application thérapeutique | |
MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
MA35064B1 (fr) | Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie | |
MA43158B1 (fr) | Composés oxa-diazadispiro possédant une activité contre la douleur | |
MA20150350A1 (fr) | Dérivés isoxazolidine | |
WO2016187620A3 (fr) | Composés anti-cancereux | |
MA38523A1 (fr) | Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma | |
MA35894B1 (fr) | Composés d'oxazolidine-2-one et utilisations de ceux-ci en tant qu'inhibiteurs des pi3k | |
FR2985256B1 (fr) | Derives piperazinyles pour le traitement de cancers | |
FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives |